RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
Rose, L, Graham, T, Pattison, N, Metaxa, V, Saha, S, Ramsay, P & Meyer, J 2022, ' Family perspectives on facilitators and barriers to the set up and conduct of virtual visiting in intensive care during the COVID-19 pandemic: a qualitative interview study ', Family perspectives on facilitators and barriers to the set up and conduct of virtual visiting in intensive care during the COVID-19 pandemic: a qualitative interview study, vol. 72, 103264, pp. 1-19 . https://doi.org/10.1016/j.iccn.2022.103264
Europe PubMed Central Lancet (London, England) RECOVERY Collaborative Group & Downey, D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Group, RECOVERY C & Dark, P 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Mumford, A D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0